Continuous Disease Management Programs (DMP) will in future be evaluated. The Federal Joint Committee (G-BA) decided on June 19 in Berlin. The evaluation should be carried out by an independent expert. In addition, the G-BA has obliged the health insurance companies to present the quality assurance measures that have been agreed between the contracting parties at state level for the DMP participants. "The focus now is on the benefits of DMP for patients, measured in terms of both disease-specific and cross-indication parameters," said Dr. med. Regina Klakow-Franck, impartial member of the G-BA. In the future there will also be comparison of the results between participants and non-participants.
In addition, the G-BA has commissioned the AQUA Institute to carry out quality assurance procedures on the basis of routine data from the health insurance companies for patients with mental illnesses and for patients with chronic kidney failure. "In the future, we want to use routine data from health insurers for cross-sector quality assurance," said Klakow-Franck. The routine data of the health insurance companies contain information from both inpatient and outpatient areas. In this way, for example, it should be possible to track what happened to patient who was operated on in hospital after his discharge (see also the article “” in this booklet). fos